Early-life Factors and Cancer Development Later in Life (R01 - Clinical Trial Not Allowed) | PA 18 529

Opportunity Information: Apply for PA 18 529

The NIH funding opportunity "Early-life Factors and Cancer Development Later in Life" (PA 18-529) is an R01 research grant program designed to push the field toward a clearer, evidence-based understanding of how exposures and events early in life shape cancer risk much later on. The central idea behind the announcement is that cancer is not only influenced by adult lifestyle and aging, but may also be partly "programmed" by biological and environmental conditions that occur during sensitive developmental windows. These windows include preconception influences from both parents (maternal and paternal factors), in utero exposures, birth and infancy conditions, puberty, adolescence, and the young adult years. Because the existing evidence base is still developing and many studies have not been able to follow people for long enough, NIH is using this FOA to stimulate more rigorous and mechanistically informed research in this area.

A major emphasis of the FOA is identifying which early-life factors are genuinely associated with later cancer development. This can include a wide range of influences, such as parental health and exposures before conception, pregnancy-related factors, fetal growth patterns, birth outcomes, infant feeding and growth trajectories, childhood and adolescent body size changes, pubertal timing, early hormonal and metabolic profiles, environmental chemical exposures, infections, diet, psychosocial stressors, and social and structural conditions that can shape biology. The opportunity is not limited to any single cancer type; rather, it aims to encourage studies that can connect early developmental exposures to cancer outcomes across the life course, including potentially cancer precursors or premalignant conditions where appropriate.

The FOA also strongly encourages research that explains how early-life factors actually "get under the skin" biologically to influence carcinogenesis. In other words, applicants are expected to move beyond simply showing correlations and to investigate plausible biological pathways that connect early exposures to later malignant transformation. This can involve studying how early-life environments influence processes such as endocrine and growth factor signaling, immune development and chronic inflammation, epigenetic programming, DNA damage and repair capacity, oxidative stress responses, tissue development and stem/progenitor cell dynamics, microbiome development, and long-term metabolic regulation. The announcement is rooted in the idea that early developmental periods may represent particularly sensitive windows when organs and regulatory systems are forming, and when exposures can have lasting effects on susceptibility to disease decades later.

A third major goal is the development and validation of predictive markers that could estimate future cancer risk based on measurable biological signals from early life. NIH highlights a practical problem in this field: waiting decades to observe cancer incidence makes it difficult to study early-life determinants efficiently. For that reason, the FOA is interested in markers that predict malignancy or premalignant changes, which could serve as intermediate endpoints. These might include molecular, cellular, imaging, or physiological markers that reflect early-life biological changes relevant to cancer development. If reliable markers can be established, researchers and clinicians could assess the impact of early-life exposures without needing to track participants until typical cancer ages, and prevention strategies could be evaluated more quickly.

The longer-term public health motivation is prevention: by understanding the mechanisms linking early-life exposures to later cancer, researchers may be able to identify actionable intervention points during pregnancy, infancy, childhood, adolescence, or early adulthood. The FOA explicitly frames this as an opportunity for potentially high-impact cancer prevention, because intervening early could shift lifetime risk trajectories before harmful pathways are entrenched. The end vision is that mechanistic clarity plus measurable risk markers could enable targeted prevention strategies, improved risk stratification, and possibly guidelines or interventions aimed at early developmental windows.

From an administrative standpoint, this is an NIH discretionary grant using the R01 mechanism, and it is labeled "Clinical Trial Not Allowed," meaning applications should not propose clinical trials as defined by NIH. The activity category is listed under Education and Health (CFDA 93.393). The original closing date shown in the source data is 2021-01-07, and the opportunity record was created on 2017-12-20. An award ceiling is not specified in the provided listing, and the expected number of awards is not stated in the excerpt.

Eligibility is broad and includes many types of organizations. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories as specified); for-profit organizations other than small businesses; and small businesses. The FOA also highlights additional eligible or encouraged applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based and community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations), as well as Indian/Native American Tribal Governments that are not federally recognized.

Overall, the opportunity is aimed at building a stronger scientific foundation for life-course cancer prevention by funding research that (1) pinpoints meaningful early-life risk factors, (2) clarifies the biological mechanisms linking those factors to carcinogenesis, and (3) develops early measurable markers that can forecast later cancer risk or premalignant outcomes, making prevention research and evaluation more feasible on realistic timelines.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Early-life Factors and Cancer Development Later in Life (R01 - Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393.
• This funding opportunity was created on 2017-12-20.
• Applicants must submit their applications by 2021-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PA 18 529

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: